Mesoblast Limited (NASDAQ:MESO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “

A number of other research analysts have also commented on MESO. BidaskClub lowered Mesoblast Limited from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Credit Suisse Group set a $11.00 price objective on Mesoblast Limited and gave the company a “hold” rating in a research report on Tuesday, July 18th. Maxim Group set a $14.00 price target on Mesoblast Limited and gave the company a “buy” rating in a research note on Wednesday, August 16th. Cantor Fitzgerald set a $20.00 price target on Mesoblast Limited and gave the company a “buy” rating in a research note on Wednesday, August 16th. Finally, Oppenheimer Holdings, Inc. assumed coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.14.

Shares of Mesoblast Limited (MESO) opened at 5.20 on Wednesday. The company’s market cap is $441.71 million. Mesoblast Limited has a 1-year low of $4.07 and a 1-year high of $12.50. The stock has a 50 day moving average price of $5.98 and a 200-day moving average price of $7.62.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Mesoblast Limited (MESO) to Hold” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/01/zacks-investment-research-downgrades-mesoblast-limited-meso-to-hold.html.

Mesoblast Limited Company Profile

Analyst Recommendations for Mesoblast Limited (NASDAQ:MESO)

Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.